No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 8
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Curanex Pharmaceuticals Inc Common Stock (CURX) stock was $4.96 as of Oct 5, 2026, 4:00 PM EDT, up 5.08% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -68.0%
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions.
Biotechnology · Jericho, NY
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.60
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CURX | $7.03M | $4.96 | +5.08% | -68.03% | N/A | N/A | N/A |
| 2KALA | $7.01M | $0.36 | -5.84% | -99.52% | -85.73% | N/A | vs CURX |
| 3CODX | $6.88M | $1.10 | +1.85% | -90.34% | -66.53% | N/A | vs CURX |
| 4ENVB | $6.76M | $1.51 | +2.03% | N/A | N/A | N/A | vs CURX |
| 5INM | $7.31M | $1.33 | +0.00% | -41.77% | -71.98% | -52.81% | vs CURX |
| 6ACON | $6.74M | $2.34 | -1.68% | -68.01% | N/A | N/A | vs CURX |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.96
High
N/A
